CARISTI N[au] - Search Results

Year	Number of Results
1985	2
1988	1
1989	2
1990	1
1991	1
1993	1
1997	1
1999	1
2001	3
2002	1
2003	2
2005	2
2007	2
2008	3
2009	1
2011	1
2012	2
2013	1
2014	1
2022	0

1

Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives.

Adamo V, Franchina T, Adamo B, Denaro N, Gambadauro P, Chiofalo G, Scimone A, Caristi N, Russo A, Giordano A. Adamo V, et al. Among authors: caristi n. Cancer Biol Ther. 2009 Feb;8(3):206-12. doi: 10.4161/cbt.8.3.7465. Epub 2009 Feb 20. Cancer Biol Ther. 2009. PMID: 19182534 Review.

2

Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients.

Adamo V, Iorfida M, Montalto E, Festa V, Garipoli C, Scimone A, Zanghì M, Caristi N. Adamo V, et al. Among authors: caristi n. Ann Oncol. 2007 Jun;18 Suppl 6:vi53-7. doi: 10.1093/annonc/mdm225. Ann Oncol. 2007. PMID: 17591833 Free article. Review.

3

Emerging targeted therapies for castration-resistant prostate cancer.

Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, Caristi N. Adamo V, et al. Among authors: caristi n. Front Endocrinol (Lausanne). 2012 May 31;3:73. doi: 10.3389/fendo.2012.00073. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 22666217 Free PMC article.

4

Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients.

Adamo V, Caristi N, Saccà MM, Ferraro G, Arcanà C, Maisano R, Santini D, Tonini G. Adamo V, et al. Among authors: caristi n. Expert Opin Pharmacother. 2008 Jun;9(8):1351-61. doi: 10.1517/14656566.9.8.1351. Expert Opin Pharmacother. 2008. PMID: 18473709 Review.

5

The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population.

Adamo V, Ricciardi GR, Adamo B, Ferraro G, Franchina T, Rossello R, Zanghì M, Cicero G, Rizzo S, Caristi N, Russo A. Adamo V, et al. Among authors: caristi n. Oncology. 2014;86(1):16-21. doi: 10.1159/000353450. Epub 2013 Dec 10. Oncology. 2014. PMID: 24335608

6

[Malignant lymphoma. Epidemiologic review of 150 cases].

Chillè G, Tomasello R, Silipigni AM, Picone GS, Chiofalo G, Rizzotti P, Caristi N, La Torre F. Chillè G, et al. Among authors: caristi n. Minerva Med. 1999 May-Jun;90(5-6):159-64. Minerva Med. 1999. PMID: 10780190 Review. Italian.

7

Venous damage prevention by defibrotide in vinorelbine-treated patients.

Mare M, Maisano R, Caristi N, Adamo V, Altavilla G, Carboni R, Munaò S, La Torre F. Mare M, et al. Among authors: caristi n. Support Care Cancer. 2003 Sep;11(9):593-6. doi: 10.1007/s00520-003-0479-z. Epub 2003 May 16. Support Care Cancer. 2003. PMID: 12750969

8

Hematopoietic progenitor cells (HPCs) in node-negative invasive breast carcinomas: Immunohistochemical analysis and clinico-pathological correlations.

Giuffrè G, Adamo V, Ieni A, Colonese F, Barresi V, Caristi N, Adamo B, Tuccari G. Giuffrè G, et al. Among authors: caristi n. Pathol Res Pract. 2011 Aug 15;207(8):487-91. doi: 10.1016/j.prp.2011.05.013. Epub 2011 Jul 14. Pathol Res Pract. 2011. PMID: 21757299

9

Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer.

Caristi N, Maisano R, Iorfida M, Scimone A, Lupo G, Buda C, Scisca C, Adamo V. Caristi N, et al. J Chemother. 2008 Jun;20(3):368-73. doi: 10.1179/joc.2008.20.3.368. J Chemother. 2008. PMID: 18606594 Clinical Trial.

10

Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?

Maisano R, Mare M, Zavettieri M, Caristi N, Mesiti M, Scisca C, La Torre F. Maisano R, et al. Among authors: caristi n. Anticancer Res. 2003 Mar-Apr;23(2C):1923-6. Anticancer Res. 2003. PMID: 12820480 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results